The Gut Microbiome and Symptom Burden After Kidney Transplantation: An Overview and Research Opportunities Biol Res Nurs. 2024 Jun 5:10998004241256031. doi: 10.1177/10998004241256031.Online ahead of print.
Mark B Lockwood 1, Choa Sung 2, Suzanne A Alvernaz 3, John R Lee 4, Jennifer L Chin 5, Mehdi Nayebpour 6, Beatriz Peñalver Bernabé 3, Lisa M Tussing-Humphreys 7, Hongjin Li 1, Mario Spaggiari 8, Alessandro Martinino 8, Chang G Park 9, George E Chlipala 10, Ardith Z Doorenbos 11, Stefan J Green 12 |
Author information 1Department of Biobehavioral Nursing Science, University of Illinois Chicago College of Nursing, Chicago, IL, USA. 2Post-Doctoral Fellow, Department of Biobehavioral Nursing Science, University of Illinois Chicago College of Nursing, Chicago, IL, USA. 3Graduate Student, Department of Biomedical Engineering, University of Illinois ChicagoColleges of Engineering and Medicine, Chicago, IL, USA. 4Division of Nephrology and Hypertension, Department of Medicine, Weill Cornell Medicine, New York, NY, USA. 5Medical Student, Touro College of Osteopathic Medicine, Middletown, NY, USA. 6Virginia BioAnalytics LLC, Washington, District of Columbia, USA. 7Department of Kinesiology and Nutrition, College of Applied Health Sciences, University of Illinois Chicago, Chicago, IL, USA. 8Division of Transplantation, Department of Surgery, University of Illinois at Chicago, Chicago, IL, USA. 9Department of Population Health Nursing Science, Office of Research Facilitation, University of Illinois Chicago, Chicago, IL, USA. 10Research Core Facility, Research Resources Center, University of Illinois Chicago, Chicago, IL, USA. 11Department of Biobehavioral Nursing Science, University of Illinois ChicagoCollege of Nursing, Chicago, IL, USA. 12Department of Internal Medicine, Division of Infectious Diseases, Rush University Medical Center, Chicago, IL, USA. Abstract Many kidney transplant recipients continue to experience high symptom burden despite restoration of kidney function. High symptom burden is a significant driver of quality of life. In the post-transplant setting, high symptom burden has been linked to negative outcomes including medication non-adherence, allograft rejection, graft loss, and even mortality. Symbiotic bacteria (microbiota) in the human gastrointestinal tract critically interact with the immune, endocrine, and neurological systems to maintain homeostasis of the host. The gut microbiome has been proposed as an underlying mechanism mediating symptoms in several chronic medical conditions including irritable bowel syndrome, chronic fatigue syndrome, fibromyalgia, and psychoneurological disorders via the gut-brain-microbiota axis, a bidirectional signaling pathway between the enteric and central nervous system. Post-transplant exposure to antibiotics, antivirals, and immunosuppressant medications results in significant alterations in gut microbiota community composition and function, which in turn alter these commensal microorganisms' protective effects. This overview will discuss the current state of the science on the effects of the gut microbiome on symptom burden in kidney transplantation and future directions to guide this field of study. |
© Copyright 2013-2024 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only.
Use of this website is governed by the GIHF terms of use and privacy statement.